Sterling Capital Management LLC Sells 10,547 Shares of Repligen Corporation $RGEN

Sterling Capital Management LLC reduced its holdings in Repligen Corporation (NASDAQ:RGEN) by 87.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 1,536 shares of the biotechnology company’s stock after selling 10,547 shares during the quarter. Sterling Capital Management LLC’s holdings in Repligen were worth $295,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of RGEN. Yousif Capital Management LLC increased its stake in shares of Repligen by 1.3% in the third quarter. Yousif Capital Management LLC now owns 12,604 shares of the biotechnology company’s stock valued at $2,423,000 after buying an additional 160 shares during the period. Crossmark Global Holdings Inc. lifted its holdings in Repligen by 3.5% in the third quarter. Crossmark Global Holdings Inc. now owns 4,525 shares of the biotechnology company’s stock valued at $870,000 after buying an additional 152 shares during the period. Diversify Advisory Services LLC boosted its position in shares of Repligen by 7.7% during the 3rd quarter. Diversify Advisory Services LLC now owns 20,028 shares of the biotechnology company’s stock valued at $3,689,000 after purchasing an additional 1,434 shares in the last quarter. Stronghold Wealth Management L.L.C. bought a new position in shares of Repligen during the 3rd quarter worth approximately $234,000. Finally, State of Alaska Department of Revenue grew its position in shares of Repligen by 2.9% during the 3rd quarter. State of Alaska Department of Revenue now owns 5,346 shares of the biotechnology company’s stock worth $1,027,000 after buying an additional 150 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Trading Down 6.2%

NASDAQ:RGEN opened at $176.94 on Friday. Repligen Corporation has a 52 week low of $100.99 and a 52 week high of $198.87. The firm has a 50-day moving average price of $178.05 and a two-hundred day moving average price of $145.23. The company has a debt-to-equity ratio of 0.27, a quick ratio of 7.64 and a current ratio of 9.88. The firm has a market cap of $9.99 billion, a price-to-earnings ratio of 92.47, a price-to-earnings-growth ratio of 3.42 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.07. The company had revenue of $209.31 million during the quarter, compared to analyst estimates of $206.70 million. Repligen had a positive return on equity of 5.49% and a negative net margin of 1.47%. Repligen’s quarterly revenue was up 10.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.46 earnings per share. On average, equities analysts expect that Repligen Corporation will post 2.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the stock. Wells Fargo & Company boosted their target price on shares of Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a research report on Thursday, July 30th. Barclays increased their price target on Repligen from $175.00 to $225.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Citigroup raised Repligen to a “buy” rating in a research report on Tuesday, July 7th. Evercore reiterated an “outperform” rating and issued a $160.00 target price on shares of Repligen in a report on Monday, July 6th. Finally, Canaccord Genuity Group upped their price objective on shares of Repligen from $145.00 to $180.00 and gave the stock a “hold” rating in a report on Monday, October 19th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, Repligen has an average rating of “Moderate Buy” and an average target price of $178.57.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.